Kathryn Falberg

Kathryn Falberg

Directeur/Membre du Conseil chez NUVATION BIO INC.

Fortune : 7 M $ au 30/06/2026

65 ans
Health Technology
Electronic Technology
Technology Services

Profil

Ms. Kathryn E.
Falberg
is an Independent Director at Nuvation Bio, Inc. and an Independent Director at Arcus Biosciences, Inc. She is on the Board of Directors at Nuvation Bio, Inc., Arcus Biosciences, Inc. and Nuvation Bio Operating Co., Inc. Ms. Falberg was previously employed as an Independent Director by Tricida, Inc., an Independent Director by UroGen Pharma Ltd., an Independent Director by The Trade Desk, Inc., an Independent Director by Aimmune Therapeutics, Inc., a Chairman by aTyr Pharma, Inc., an Independent Director by Medivation LLC (California), a Chief Financial Officer & Senior Vice President by Azur Pharma Ltd., a Chief Financial Officer & Executive Vice President by Jazz Pharmaceuticals Plc, a Chief Financial Officer & Executive Vice President by Jazz Pharmaceuticals, Inc., an Independent Director by QLT, Inc., a Chief Operating & Financial Officer by ARCA biopharma, Inc., a Chairman by Halozyme Therapeutics, Inc., a President by Canyon Capital & Consulting, Inc., a Chief Financial Officer by Inamed Corp., a Chief Financial Officer, SVP-Finance & Strategy by Amgen, Inc., a Chief Financial Officer & Director by AdECN, Inc., and a Chief Financial Officer, Treasurer & VP by Applied Magnetics Corp.
She also served on the board at Axovant Sciences, Inc., Axovant Gene Therapies Ltd., BioMarin Pharmaceutical, Inc., Ariosa Diagnostics, Inc., Medivation, Inc. /Old/, Human Genome Sciences, Inc., Fresh Del Monte Produce, Inc., AMO Manufacturing USA LLC, ESS Technology, Inc. and Roivant Sciences GmbH.
She received her undergraduate degree from the University of California, Los Angeles and an MBA from the University of California, Los Angeles.

Détentions connues dans des sociétés publiques

SociétéDateNombre d'actionsValorisationDate de valorisation
11/06/2026 176 406 ( 0,14 % ) 5 M $ 30/06/2026
21/05/2026 250 000 ( 0,07 % ) 1 M $ 30/06/2026

Postes actifs de Kathryn Falberg

SociétésPosteDébut
ARCUS BIOSCIENCES, INC. Directeur/Membre du Conseil 18/09/2017
NUVATION BIO INC. Directeur/Membre du Conseil 01/10/2020
Directeur/Membre du Conseil -

Anciens postes connus de Kathryn Falberg

SociétésPosteFin
THE TRADE DESK, INC. Directeur/Membre du Conseil 23/03/2026
TRICIDA, INC. Directeur/Membre du Conseil 01/06/2023
UROGEN PHARMA LTD. Directeur/Membre du Conseil 08/06/2022
AIMMUNE THERAPEUTICS, INC. Directeur/Membre du Conseil 01/10/2020
SIO GENE THERAPIES INC. Directeur/Membre du Conseil 01/02/2018
Voir l'expérience en détail de Kathryn Falberg

Formation de Kathryn Falberg

Expériences
Fonctions occupées

Actives

Inactives

Sociétés cotées

Entreprise privées

Relations

86

Relations au 1er degré

31

Entreprises liées au 1er degré

Homme

Femme

Administrateurs

Exécutifs

Sociétés liées

Entreprise privées31

Health Technology

Electronic Technology

Health Technology

Health Technology

Health Technology

Commercial Services

Electronic Technology

Process Industries

Health Technology

Health Technology

Health Technology

Health Technology

Health Technology

Consumer Services

Health Technology

Health Technology

Health Technology

Technology Services

Health Technology

Technology Services

Canyon Capital & Consulting, Inc.

Health Services

Health Technology

Health Technology

Health Technology

Health Technology

Health Technology

Health Technology

Health Technology

Health Technology

Health Technology

  1. Bourse
  2. Insiders
  3. Kathryn Falberg
🔇